AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Cell International"
DOI: 10.1186/s12935-019-1059-8
Abstract: BackgroundTreatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manufacturing processes… read more here.
Keywords: anti antibody; melanoma models; anti gal; agi 134 ... See more keywords